Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
National Cancer Institute (NCI)
Helsinki University Central Hospital
OHSU Knight Cancer Institute
Novartis